Publications
Goto, A., Tagawa, Y., Moriya, Y., Sato, S., Furukawa, Y., Wakabayashi, T., Tsukamoto T., Jongh J.d, Steeg T.J.v., Moriwaki T., Asahi, S. Impact of acute fat mobilisation on the pharmacokinetics of the highly fat distributed compound TAK-357, investigated by physiologically based pharmacokinetic (PBPK) modeling and simulation. Biopharmaceutics & Drug Disposition, 373–380, 2017. [Link to publication]
Gosset J.R., Beaumont K., Matsuura T., Winchester W., Attkins N., Glatt S.,Lightbown I., Ulrich K., Roberts S., Harris J., Mesic E., Steeg T.J.v., Hijdra D., Graaf P.H.v.d. A cross-species translational pharmacokinetic-pharmacodynamic evaluation of core body temperature reduction by the TRPM8 blocker PF-05105679. European Journal of Pharmaceutical Sciences: S161-S167 2017. [Link to publication]
Garmann D., McLeay S., Shah A., Vis P., Maas Enriquez M., Ploeger, B.A. Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned ‒ importance of including samples with factor VIII levels below the quantitation limit. Haemophilia: 528–537, 2017. [Link to publication]
Solms A., Reinecke I., Fiala-Buskies S., Keunecke A., Drenth H.J., Bruix, J., Meinhardt G., Cleton A., Ploeger, B. Exposure-response relationship of regorafenib efficacy in patients with hepatocellular carcinoma. European Journal of Pharmaceutical Sciences: S149-S153, 2017. [Link to publication]
van Maanen, E.M., , van Steeg, T.J., Michener, M.S., Savage, M.J., Kennedy, M.E., Kleijn, H.J., Stone, J.A., Danhof, M. Systems Pharmacology Analysis of the Amyloid Cascade after beta-Secretase Inhibition Enables the Identification of an Abeta42 Oligomer Pool. J Pharmacol Exp Ther., 357(1): 205-216. 2016 [Link to publication].
van Steeg T.J., Bergmann K.R., Dimasi N., Sachsenmeier K.F. and Agoram B., The application of mathematical modelling to the design of bispecific monoclonal antibodies, MAbs., 8(3): 585-592. doi: 510.1080/19420862.19422016.11141160. Epub 19422016 Feb 19420824., 2016. [Link to publication]
Huntjens D.R., Liefaard L.C., Nandy P., Drenth H.J. and Vermeulen A., Population Pharmacokinetic Modeling of Tapentadol Extended Release (ER) in Healthy Subjects and Patients with Moderate or Severe Chronic Pain, Clin Drug Investig., 36(3): 213-223. 2016. [Link to publication]
Snelder N., Ploeger B.A., Luttringer O., Rigel D.F., Webb R.L., Feldman D., Fu F., Beil M., Jin L., Stanski D.R. and Danhof M., Characterization and prediction of cardiovascular effects of fingolimod and siponimod using a systems pharmacology modelling approach, J Pharmacol Exp Ther, 1(116): 236208, 2016. [Link to publication]
Berkhout J., Stone J.A., Verhamme K.M., Stricker B.H., Sturkenboom M.C., Danhof M., and Post T.M., Application of a Systems Pharmacology-Based Placebo Population Model to Analyze Long-Term Data of Postmenopausal Osteoporosis, CPT Pharmacometrics Syst Pharmacol., 4(9): 516-526. 2015. [Link to publication]
Brochot A., Kakuda T.N., Van De Casteele T., Opsomer M., Tomaka F.L., Vermeulen A. and Vis P., Model-Based Once-Daily Darunavir/Ritonavir Dosing Recommendations in Pediatric HIV-1-Infected Patients Aged >/=3 to <12 Years, CPT Pharmacometrics Syst Pharmacol., 4(7): 406-414. 2015. [Link to publication]